NUVB Nuvation Bio Inc.

QT26

Latest market price

4.70

+0.11+2.29%

Overview Short InterestFilings

NUVBQT26Nuvation Bio Inc.·NYSE

Overview Short InterestFilings

4.70+2.29%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

RARE+2.56%$16.72 TRAX+1.65%$45.80 QURE+2.00%$23.43 NTLA+4.63%$12.20 KLRA+4.36%$12.68 ABSI+5.78%$10.25 URGN-0.82%$34.08 MAZE+2.22%$31.05

Snapshot

Index	—	P/E	—	EPS (ttm)	-0.44	Insider Own	43.38%	Shs Outstand	350.12M	Perf Week	1.77%

Market Cap	1.61B	Forward P/E	—	EPS next Y	-0.21	Insider Trans	-0.20%	Shs Float	251.98M	Perf Month	-10.70%

Enterprise Value	1.20B	PEG	—	EPS next Q	-0.12			Short Float	25.09%	Perf Quarter	-28.73%

Income	-151.00M	P/S	9.45	EPS this Y	—			Short Ratio	11.25	Perf Half Y	4.08%

Sales	170.00M	P/B	6.33	EPS next Y	—	ROA	-20.12%	Short Interest	63.22M	Perf YTD	-48.77%

Book/sh	0.73	P/C	2.43	EPS next 5Y	—	ROE	-49.73%	52W High	9.75 -51.85%	Perf Year	-10.87%

Cash/sh	1.89	P/FCF	—	EPS past 3/5Y	—	ROIC	-20.68%	52W Low	3.92 19.77%	Perf 3Y	309.82%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	93.94%	Volatility	4.61% 4.92%	Perf 5Y	-53.92%

Dividend TTM	—	EV/Sales	7.04	EPS Y/Y TTM	—	Oper. Margin	-81.00%	ATR (14)	0.25	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	8.14	Sales Y/Y TTM	1033.33%	Profit Margin	-88.19%	RSI (14)	37.90	Recom	2.20

Dividend Gr. 3/5Y	—	Current Ratio	8.37	EPS Q/Q	11.76%	SMA20	-2.68%	Beta	1.70	Target Price	—

Payout	0.00%	Debt/Eq	0.99	Sales Q/Q	540.00%	SMA50	-17.84%	Rel Volume	0.70	Prev Close	4.59

Employees	305	LT Debt/Eq	0.96	Earnings	Nov 04	SMA200	-14.84%	Avg Volume	5.33M	Price	4.70

IPO Date	Aug 26, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.89% —	Net Debt/EBITDA	—	Volume	3,723,263	Change	2.29%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-07-26	Reiterated	RBC Capital	Outperform
Jul-27-26	Reiterated	HC Wainwright & Co.	Buy	$17
Jul-07-26	Reiterated	RBC Capital	Outperform	$12
Jan-27-26	Reiterated	Truist Financial		$11 → $13
Jan-21-26	Reiterated	RBC Capital	Outperform	$5.00 → $12
Jan-12-26	Reiterated	HC Wainwright & Co.	Buy	$18 → $17
Jan-07-26	Reiterated	UBS		$10
Dec-11-25	Reiterated	HC Wainwright & Co.	Buy	$10 → $18
Dec-01-25	Reiterated	HC Wainwright & Co.	Buy	$7.00 → $10
Nov-24-25	Initiated	Truist	Buy	$11

Latest News· Times ET

Nov-02-26

Nov-02-2608:00AM

Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meetingprnewswire.com

04:06AM

Nuvation Bio To Present Updated Data From Its Phase 2 J201 Trial, Three Posters On Ongoing Studies Of Safusidenib At Society For Neuro-Oncology Annual MeetingBenzinga

Oct-29-26

Oct-29-2608:00AM

Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countriesprnewswire.com

Oct-24-26

Oct-24-2609:13AM

Nuvation Bio And 2 More Penny Stocks To WatchYahoo

Oct-21-26

Oct-21-2604:05PM

Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026prnewswire.com

Oct-17-26

Oct-17-2609:13PM

Nuvation Bio And 2 Penny Stocks To WatchYahoo

Oct-10-26

Oct-10-2608:13PM

Top 3 Penny Stocks To Watch In October 2026Yahoo

Oct-02-26

Oct-02-2609:11PM

Top Penny Stocks To Own In October 2026Yahoo

Sep-30-26

Sep-30-2604:30PM

Citigroup Initiates Coverage of Nuvation Bio with BuyFintel

06:44AM

Nuvation Bio Inc. (NYSE:NUVB) Stock Rated “Moderate Buy” by Wall Street Analystsdefenseworld.net

Sep-18-26

Sep-18-2605:22AM

5 Undervalued Oncology Stocks Wall Street Is OverlookingSeekingAlpha

Sep-17-26

Sep-17-2607:30AM

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancerprnewswire.com

Sep-16-26

Sep-16-2604:59AM

Citizens Reiterates Market Outperform on Nuvation Bio, Maintains $10 Price TargetBenzinga

Sep-15-26

Sep-15-2612:11PM

Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcriptseekingalpha.com

08:00AM

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancerprnewswire.com

Company

Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	170	63	8	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	10	8	7	0	—	—	—	—	—
Gross Profit	160	54	1	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	158	152	69	29	—	—	—	—	—
Research and Development	129	115	524	71	—	—	—	—	—
Other Operating Expense	10	1	0	0	—	—	—	—	—
Operating Income	-137	-213	-593	-100	—	—	—	—	—
Interest Expense	28	14	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	14	22	25	24	—	—	—	—	—
Net Income Before Taxes	-151	-205	-568	-76	—	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—	—
Consolidated Net Income	-151	-205	-568	-76	—	—	—	—	—
Net Income From Continuing Operations	-151	-205	-568	-76	—	—	—	—	—
Net Income	-151	-205	-568	-76	—	—	—	—	—
EPS (Recurring)	-0.43	-0.60	-2.11	-0.35	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.43	-0.60	-2.11	-0.35	—	—	—	—	—
EPS (Diluted)	-0.44	-0.60	-2.11	-0.35	—	—	—	—	—
EBITDA	-127	-189	-567	-76	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	9.64	48.64	89.44	—	—	—	—	—	—
Gross Margin	94.12	85.71	12.50	—	—	—	—	—	—
Operating Margin	-80.59	-338.10	-7,412.50	—	—	—	—	—	—
Net Margin	-88.82	-325.40	-7,100.00	—	—	—	—	—	—
Shares Outstanding	349	342	269	219	—	—	—	—	—
Market Capitalization	1,639	3,064	716	331	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Aug 19 '26	Option Exercise	1.87	100,000	187,000	100,000	Aug 21
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Aug 19 '26	Sale	7.09	100,000	709,240	0	Aug 21
Sauvage Philippe	Chief Financial Officer	Jul 15 '26	Option Exercise	2.17	40,000	86,800	54,131	Jul 17
Wentworth Kerry	CHIEF REGULATORY OFFICER	Jun 23 '26	Sale	6.02	63,000	379,191	53,000	Jun 24
Sauvage Philippe	Chief Financial Officer	Jun 23 '26	Option Exercise	2.17	47,668	103,440	60,341	Jun 24
Sauvage Philippe	Chief Financial Officer	Jun 23 '26	Sale	6.01	47,668	286,370	12,673	Jun 24
Markel Stacy	CHIEF PEOPLE OFFICER	Jun 23 '26	Option Exercise	1.83	125,000	229,250	157,591	Jun 24
Markel Stacy	CHIEF PEOPLE OFFICER	Jun 23 '26	Sale	6.03	125,000	753,188	32,591	Jun 24
Wentworth Kerry	CHIEF REGULATORY OFFICER	Jun 23 '26	Option Exercise	2.93	63,000	184,590	116,000	Jun 24
Mashal Robert	Director	Jun 09 '26	Buy	4.73	25,000	118,250	225,000	Jun 11
Wentworth Kerry	CHIEF REGULATORY OFFICER	Apr 17 '26	Option Exercise	2.93	36,750	107,678	89,750	Apr 21
Wentworth Kerry	CHIEF REGULATORY OFFICER	Apr 17 '26	Sale	5.01	36,750	184,279	53,000	Apr 21
Liu Dongfang	CHIEF MEDICAL OFFICER	Apr 17 '26	Option Exercise	1.94	50,000	97,000	68,000	Apr 21
Liu Dongfang	CHIEF MEDICAL OFFICER	Apr 17 '26	Sale	5.02	50,000	251,000	18,000	Apr 21
Wentworth Kerry	CHIEF REGULATORY OFFICER	Apr 06 '26	Option Exercise	1.91	200,000	381,000	253,000	Apr 08

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.